Search results for "Food and drug administration"

showing 10 items of 24 documents

Fluorine-Containing Drugs Approved by the FDA in 2018

2019

Over the last two decades, fluorine substitution has become one of the essential structural traits in modern pharmaceuticals. Thus, about half of the most successful drugs (blockbuster drugs) contain fluorine atoms. In this review, we profile 17 fluorine-containing drugs approved by the food and drug administration (FDA) in 2018. The newly approved pharmaceuticals feature several types of aromatic F and CF3 , as well as aliphatic (CF2 ) substitution, offering advances in the treatment of various diseases, including cancer, HIV, malarial and smallpox infections.

010405 organic chemistryChemistryUnited States Food and Drug AdministrationOrganic ChemistryHuman immunodeficiency virus (HIV)Fluorine containingGeneral ChemistryPharmacology010402 general chemistrymedicine.disease_causesynthesis:01 natural sciencesCatalysisUnited Statesdrugs0104 chemical sciencesFood and drug administrationfluorinemedicineHumansfluorine; synthesis: drugs
researchProduct

Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cance…

2021

Background: The addition of PD-L1 inhibitors to platinum-based chemotherapy (CT) has newly received United States Food and Drug Administration (FDA) approval in extensive stage-small cell lung cancer (ES-SCLC). PD-1 agents similarly improved survival rates, even if not yet supported by international regulatory agencies. The current work aims to assess different efficacy and safety profiles among chemoimmunotherapy plus immuno-oncology (CT+IO) approaches according to different immune checkpoint inhibitor (ICI) subtypes. Material & Methods: We included in our meta-analysis six first-line randomised controlled trials (RCTs) comparing the association of single-agent ICI with CT versus CT al…

0301 basic medicineOncologymedicine.medical_specialtyImmunotherapy for Lung Cancer: Progress Opportunities and Challengesmedicine.medical_treatmentCellFood and drug administration03 medical and health sciences0302 clinical medicineInternal medicinemedicinechemo-immunotherapy ES-SCLC indirect comparison meta-analysis PD-L1/PD-1 inhibitorsChemo immunotherapyRC254-282ChemotherapyLungbusiness.industryPD-L1/PD-1 inhibitorsNeoplasms. Tumors. Oncology. Including cancer and carcinogensIndirect comparison030104 developmental biologymedicine.anatomical_structureOncologyindirect comparison030220 oncology & carcinogenesisMeta-analysischemo-immunotherapybusinessExtensive-stage small cell lung cancerES-SCLCMeta-AnalysisTherapeutic Advances in Medical Oncology
researchProduct

Identification of novel compounds against three targets of SARS CoV-2 coronavirus by combined virtual screening and supervised machine learning.

2021

Coronavirus disease 2019 (COVID-19) is a major threat worldwide due to its fast spreading. As yet, there are no established drugs available. Speeding up drug discovery is urgently required. We applied a workflow of combined in silico methods (virtual drug screening, molecular docking and supervised machine learning algorithms) to identify novel drug candidates against COVID-19. We constructed chemical libraries consisting of FDA-approved drugs for drug repositioning and of natural compound datasets from literature mining and the ZINC database to select compounds interacting with SARS-CoV-2 target proteins (spike protein, nucleocapsid protein, and 2′-o-ribose methyltransferase). Supported by…

0301 basic medicineSimeprevirArtificial intelligencevirusesMERS Middle East Respiratory SyndromeHealth InformaticsBiologyMachine learningcomputer.software_genremedicine.disease_causeAntiviral AgentsArticleWHO World Health OrganizationAUC area under the curve03 medical and health sciences0302 clinical medicinessRNA single-stranded RNA virusmedicineChemotherapyHumansSARS severe acute respiratory syndromeCOVID-19 coronavirus disease 2019CoronavirusNatural productsVirtual screeningACE2 angiotensin converting enzyme 2Drug discoverybusiness.industrySARS-CoV-2COVID-19LBE lowest binding energyFDA Food and Drug AdministrationROC receiver operating characteristicComputer Science ApplicationsHIV human immunodeficiency virusMolecular Docking SimulationDrug repositioning030104 developmental biologyDrug developmentSevere acute respiratory syndrome-related coronavirusParitaprevirInfectious diseasesRespiratory virusArtificial intelligenceSupervised Machine Learningbusinesscomputer030217 neurology & neurosurgeryComputers in biology and medicine
researchProduct

Statement of the Prolamin Working Group on the Determination of Gluten in Fermented Foods Containing Partially Hydrolyzed Gluten

2021

On August 12, 2020, the U.S. Food and Drug Administration (FDA) has finalized a rule related to gluten-free labeling for foods containing fermented, hydrolyzed ingredients. The FDA believes that there is no scientifically valid analytical method effective for determining gluten in fermented or hydrolyzed foods. In the absence of an analytical method, the FDA has decided to evaluate gluten-free claims on these foods based only on evidence that the food or ingredient used is gluten-free before fermentation or hydrolysis. For example, barley-based beers from which gluten is removed during brewing using special filtration, adsorption and/or enzymatic treatment are therefore excluded from bearin…

0301 basic medicineanalysifermented foodanalysisEndocrinology Diabetes and MetabolismIngredientProlaminFood scienceIngredient0302 clinical medicinehydrolysed beer[SDV.IDA]Life Sciences [q-bio]/Food engineeringFood scienceFermentation in food processingComputingMilieux_MISCELLANEOUS2. Zero hungerchemistry.chemical_classificationNutrition and DieteticsbiologyChemistryHydrolysisdigestive oral and skin physiologyfood and beveragesQuímicaChemistryFermentation in food processingProlamin Working Groupgluten-free foodpartially hydrolyzed glutenlcsh:Nutrition. Foods and food supplyLife sciences; biologyOpinioncompetitive ELISAlcsh:TX341-641030209 endocrinology & metabolismdigestive systemFood and drug administration03 medical and health sciencesHydrolysisddc:570ProlaminLC-MS/MSFood and drug administrationNutrition030109 nutrition & dieteticsbusiness.industrynutritional and metabolic diseasesBrewingGlutendigestive system diseasesPlant BreedingglutenFermentationbiology.proteinBrewingFermentation[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusiness[SDV.AEN]Life Sciences [q-bio]/Food and Nutritionceliac diseaseFrontiers in Nutrition
researchProduct

Validation of the STA-Liatest DDi assay for exclusion of proximal deep vein thrombosis according to the latest Clinical and Laboratory Standards Inst…

2018

: Recommended strategy for venous thromboembolism (VTE) diagnosis includes the use of sensitive D-dimer (DDi) assays along with pretest probability (PTP) assessment. The Clinical and Laboratory Standards Institute (CLSI) recently issued a guideline (US FDA endorsed) on DDi in VTE exclusion. Such guideline specifies the ideal D-dimer assay characteristics and target population. Demonstrate STA-LiatestD-Di performance combined with a PTP score for proximal deep vein thrombosis (pDVT) exclusion in a CLSI compliant study. International, multicenter, prospective nonrandomized, noninterventional clinical outcome management study conducted in a standard-of-care setting. DDi was measured in DVT-sus…

AdultMalemedicine.medical_specialtyDeep veinShort Communications030204 cardiovascular system & hematologySensitivity and SpecificityFibrin Fibrinogen Degradation ProductsSTA-Liatest DDi03 medical and health sciences0302 clinical medicineInternal medicineOutpatientsD-dimermedicineHumansProspective StudiesProspective cohort studyexclusiondeep venous thrombosisAgedVenous ThrombosisUnited States Food and Drug Administrationbusiness.industryImmunoturbidimetryHematologyGeneral MedicineGuidelineMiddle Agedmedicine.diseaseThrombosisUnited StatesPulmonary embolismClinical trialPre- and post-test probabilitymedicine.anatomical_structureD-dimerFemalebusiness030215 immunologyBlood Coagulation & Fibrinolysis
researchProduct

A CASCADE of effects of bisphenol A

2009

International audience

Bisphenol AHalogenation[SDV]Life Sciences [q-bio]AGENT ENDOCRINOTOXIQUEEndocrine Disruptors010501 environmental sciencesToxicologyPhotochemistry01 natural scienceschemistry.chemical_compoundGovernment regulationPregnancyENDOCRINE DISRUPTIONRISK ASSESSMENTComputingMilieux_MISCELLANEOUSmedia_common0303 health sciencesChemistryEuropeCascadeFemaleCanadamedicine.medical_specialtyFood Contamination03 medical and health sciencesHORMONE RECEPTORSFetusPhenolsInternal medicinemedicineAnimalsHumansmedia_common.cataloged_instance[INFO]Computer Science [cs]European UnionLOW-DOSE EFFECTS DEVELOPMENTBenzhydryl CompoundsEuropean union030304 developmental biology0105 earth and related environmental sciencesDose-Response Relationship DrugUnited States Food and Drug AdministrationInfant NewbornÉVALUATION RISQUEInfant newbornUnited StatesRatsEndocrinologyGovernment RegulationBISPHENOL A
researchProduct

Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers

2011

Abstract Purpose: To facilitate development of innovative immunotherapy approaches, especially for treatment concepts exploiting the potential benefits of personalized therapy, there is a need to develop and validate tools to identify patients who can benefit from immunotherapy. Despite substantial effort, we do not yet know which parameters of antitumor immunity to measure and which assays are optimal for those measurements. Experimental Design: The iSBTc-SITC (International Society for Biological Therapy of Cancer-Society for Immunotherapy of Cancer), FDA (Food and Drug Administration), and NCI (National Cancer Institute) partnered to address these issues for immunotherapy of cancer. Here…

Cancer ResearchPathologymedicine.medical_specialtyHealth Planning Guidelinesmedicine.medical_treatmentConsensus Development Conferences as TopicStandardized testImmune monitoringt-cell immunity cytokine flow-cytometry cancer vaccine consortium colony-stimulating factor b elispot assay phase-ii trial dendritic cells clinical-trials hiv vaccine harmonization guidelinesMedical OncologyArticleFood and drug administrationNeoplasmsmedicineBiomarkers TumorHumansMedical physicsPersonalized therapySocieties MedicalAntitumor immunitybusiness.industryQuality assessmentUnited States Food and Drug AdministrationCancerInternational AgenciesImmunotherapymedicine.diseaseNational Cancer Institute (U.S.)United StatesOncologyPractice Guidelines as TopicImmunotherapybusiness
researchProduct

Cardiovascular Damage in Clinical Trials

2018

The Cardio-oncology field has grown considerably in the last two decades. The remarkable increase in the number of molecules used in oncology has brought with it a huge set of cardiovascular adverse events. For this reason, it is necessary to intervene on the early stages of drug development. This is what the Food and Drug Administration aims to do. This purpose can be achieved through a more careful analysis of the adverse event, development of guidelines, and identification of objective parameters that could guide the researcher in defining precisely the adverse event. It is also necessary to use additional methods not yet used in clinical trials that can allow an early detection of adver…

Cardiotoxicitymedicine.medical_specialtybusiness.industryfood and beveragesEarly detectionClinical trialFood and drug administrationDrug developmentmedicineCardio oncologyIntensive care medicineAdverse effectSet (psychology)business
researchProduct

A survey of mycotoxins in random street-vended snacks from Lagos, Nigeria, using QuEChERS-HPLC-MS/MS

2013

Abstract A survey in African snacks was carried out in order to evaluate the intake of 23 mycotoxins. The African snack samples were purchased from street vendors within Lagos metropolis (Nigeria) and evaluated for the presence of 23 mycotoxins using a modified QuEChERS procedure coupled with liquid chromatography-triple quadrupole linear ion trap mass spectrometer. The snacks included akara, baked coconut, coconut candy, donkwa, groundnut cake (kulikuli), lafun, milk curd (wara), fresh and dried tiger-nuts, and yam flour. Only three mycotoxins were detected in 23.8% of the studied snacks, and at concentrations ranging from 6 to 54 μg kg−1. The concentrations of aflatoxin B1 (AFB1) and AFB2…

CassavaAflatoxinCoconutMycotoxinsQuechersFood and drug administrationGroundnutchemistry.chemical_compoundHplc ms mschemistryFood scienceLC-MS/MSSnacksMycotoxinFood ScienceBiotechnologyMathematicsFood Control
researchProduct

Targeted Therapies in Hepatocellular Carcinoma

2015

Hepatocellular carcinoma (HCC) is one of the main causes of death in patients affected by chronic liver diseases. The awareness of the biomolecular mechanisms underlying the complex carcinogenic process led to the development of targeted molecules, which are able to block this process. Sorafenib is a tyrosine-kinase inhibitor, and currently, it is the only drug approved by the US Food and Drug Administration (FDA) for the treatment of HCC. However, some studies have demonstrated the efficacy of single drug therapies or combination therapies. They showed an improvement with regard to overall survival, time to progression, and progression-free survival, although these therapies were not free …

DrugOncologySorafenibmedicine.medical_specialtyCirrhosisbusiness.industrymedia_common.quotation_subjectmedicine.medical_treatmentPharmacologymedicine.diseasedigestive system diseasesFood and drug administrationLiver diseaseInternal medicineHepatocellular carcinomamedicineIn patientbusinessAdjuvantmedia_commonmedicine.drug
researchProduct